Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ScTIL injection in advanced digestive or urinary system tumors
NCT05499715Phase 1Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ScTIL in digestive system neoplasm and urologic neoplasm, sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
ScTIL
03
Conditions
digestive system neoplasmurologic neoplasm
Beyond the preview
Go deeper on NCT05499715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499715.